| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2207-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0023 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y101-03004 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-04 |
| filingDate |
2016-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107530296-B |
| titleOfInvention |
Glucose-responsive insulin delivery system using hypoxia-sensitive nanocomposites |
| abstract |
A closed loop insulin delivery system is disclosed. More specifically, the insulin delivery systems of the present disclosure can comprise glucose-responsive vesicles that release insulin in response to hypoxia triggered by the enzymatic reduction of glucose. Additionally or as an alternative to insulin, the delivery system may release other diabetes therapeutics, such as non-insulin-based diabetes therapeutics. Vesicles can be prepared from hypoxia-sensitive polymers, such as hypoxia-sensitive hyaluronic acid (HS‑HA). HS‑HA may contain hydrophobic groups that can be reduced in an oxygen-deficient environment to form hydrophilic groups. The vesicles can be loaded into microneedles and microneedle array patches used to treat diabetes or otherwise modulate blood glucose levels in a subject in need of such treatment. |
| priorityDate |
2015-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |